PROSPER: Prospective Real World Outcomes Study of Hepatic Encephalopathy Patients' Experience on Rifaximin-α (TARGAXAN/XIFAXAN) 550 mg
Phase of Trial: Phase IV
Latest Information Update: 29 Jan 2018
At a glance
- Drugs Rifaximin (Primary)
- Indications Hepatic encephalopathy
- Focus Therapeutic Use
- Acronyms PROSPER
- Sponsors Norgine
- 29 Jan 2018 According to a Norgine media release, study design is publised in the Hepatology Medicine and Policy Journal. Results from the study is anticipated in 2018.
- 10 Dec 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 06 Jul 2015 New trial record